$3.64
0.28% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
CA03879J1003
Symbol
ABUS
Sector
Industry

Arbutus Biopharma Corporation Target price 2024 - Analyst rating & recommendation

Arbutus Biopharma Corporation Classifications & Recommendation:

Buy
80%
Hold
20%

Arbutus Biopharma Corporation Price Target

Target Price $5.10
Price $3.64
Potential
Number of Estimates 5
5 Analysts have issued a price target Arbutus Biopharma Corporation 2025 . The average Arbutus Biopharma Corporation target price is $5.10. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 4 Analysts recommend Arbutus Biopharma Corporation to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Arbutus Biopharma Corporation stock has an average upside potential 2025 of . Most analysts recommend the Arbutus Biopharma Corporation stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 18.14 6.18
53.51% 65.92%
Net Margin -459.50% -1,188.98%
105.75% 158.75%

5 Analysts have issued a sales forecast Arbutus Biopharma Corporation 2024 . The average Arbutus Biopharma Corporation sales estimate is

$6.2m
Unlock
. This is
8.28% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$6.7m 0.59%
Unlock
, the lowest is
$5.9m 12.46%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $18.1m 53.51%
2024
$6.2m 65.92%
Unlock
2025
$5.2m 15.98%
Unlock
2026
$8.4m 62.02%
Unlock
2027
$9.3m 10.00%
Unlock
2028
$56.4m 509.32%
Unlock

5 Arbutus Biopharma Corporation Analysts have issued a net profit forecast 2024. The average Arbutus Biopharma Corporation net profit estimate is

$-73.5m
Unlock
. This is
9.77% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-72.0m 11.62%
Unlock
, the lowest is
$-75.8m 6.97%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-83.4m 4.35%
2024
$-73.5m 11.82%
Unlock
2025
$-64.8m 11.85%
Unlock
2026
$-77.7m 19.88%
Unlock
2027
$-34.1m 56.10%
Unlock
2028
$-43.6m 27.77%
Unlock

Net Margin

2023 -459.50% 105.75%
2024
-1,188.98% 158.75%
Unlock
2025
-1,247.28% 4.90%
Unlock
2026
-922.89% 26.01%
Unlock
2027
-368.32% 60.09%
Unlock
2028
-77.24% 79.03%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.44 -0.39
4.35% 11.36%
P/E negative
EV/Sales 92.00

5 Analysts have issued a Arbutus Biopharma Corporation forecast for earnings per share. The average Arbutus Biopharma Corporation <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.39
Unlock
. This is
9.30% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.38 11.63%
Unlock
, the lowest is
$-0.40 6.98%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.44 4.35%
2024
$-0.39 11.36%
Unlock
2025
$-0.34 12.82%
Unlock
2026
$-0.41 20.59%
Unlock
2027
$-0.18 56.10%
Unlock
2028
$-0.23 27.78%
Unlock

P/E ratio

Current -8.54 124.74%
2024
-9.38 9.84%
Unlock
2025
-10.64 13.43%
Unlock
2026
-8.88 16.54%
Unlock
2027
-20.22 127.70%
Unlock
2028
-15.83 21.71%
Unlock

Based on analysts' sales estimates for 2024, the Arbutus Biopharma Corporation stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

92.00
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
111.57
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 84.38 987.37%
2024
92.00 9.03%
Unlock
2025
109.49 19.01%
Unlock
2026
67.58 38.28%
Unlock
2027
61.43 9.09%
Unlock
2028
10.08 83.59%
Unlock

P/S ratio

Current 102.34 666.79%
2024
111.57 9.03%
Unlock
2025
132.79 19.01%
Unlock
2026
81.96 38.28%
Unlock
2027
74.50 9.09%
Unlock
2028
12.23 83.59%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today